- Fluvastatin
- Fluvastatin Sodium
- Atorvastatin Calcium
- Pravastatin sodium
- Pitavastatin Calcium
| LovastatinHMG-CoA reductase inhibitor |
Sample solution is provided at 25 µL, 10mM.
Nature.2017 Jan 19;541(7637):417-420.
Nature.2018 Nov;563(7731):407-411.Nature.2018 Jun 13.Nature.2018 Jun 27.Nature.2018 Mar 29;555(7698):673-677.Nature.2017 Sep 7;549(7670):96-100.Nature.2016 Apr 21;532(7599):398-401.
Science.2016 Aug 5;353(6299)594-8Nat Nanotechnol.2017 Dec;12(12):1190-1198.Nature Biotechnology.2017 Jun;35(6):569-576Nat Med.2018 Sep 17.Cell.2018 Dec 21. pii: S0092-8674(18)31561-7.Cell.Available online 25 October 2018.Cell.2018 Sep 27. pii: S0092-8674(18)31183-8.Cell.2018 Jun 28;174(1):172-186.e21.Cell.2018 Feb 22;172(5):1007-1021.e17.Cell.2017 Nov 30;171(6):1284-1300.e21.Cell.2017 Aug 17. pii: S0092-8674(17)30869-3.Cell.2017 Jul 13;170(2):312-323Nat Med.2018 Jan 29.Nat Med.2017 Nov;23(11):1342-1351.Cell.2017 Apr 6;169(2):286-300.Cell.2015 Aug 27;162(5):987-1002.Cell.2015 Feb 12;160(4):729-44.Nature Medicine.2017 Apr;23(4):493-500.Cancer Cell.2018 May 14;33(5):905-921.e5.Cancer Cell.2018 Apr 9;33(4):752-769.e8.Cancer Cell.2018 Mar 12;33(3):401-416.e8.Cancer Cell.2017 Aug 14;32(2):253-267.e5.Nat Methods.2018 Jul;15(7):523-526.Cell Stem Cell.2018 May 3;22(5):769-778.e4.Cell Stem Cell.2017 Nov 20. pii: S1934-5909(17)30375-2.Quality Control & MSDS
- View current batch:
- Purity = 98.58%
- COA (Certificate Of Analysis)
- HPLC (Retest)
- NMR (Nuclear Magnetic Resonance)
- MSDS (Material Safety Data Sheet)
- Datasheet
Chemical structure
| Cell experiment [1]: | |
Cell lines | HeLa, MCF-7 and HepG2 cell lines |
Preparation method | The solubility of this compound in DMSO is >20.2 mg/ml. General tips for obtaining a higher concentration: Please warm the tube at 37℃ for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below -20℃ for several months. |
Reacting condition | 5-1600 μg/ml |
Applications | Lovastatin, other than its anticholesterol property, has diverse applications in the field of osteoporosis, neuro-degeneration, rheumatoid arthritis, antifungals and also is reported to reduce proliferation of lung cancer cells, breast cancer (MCF-7), liver cancer (HepG2). Lovastatin treatments show significant dose dependent cytotoxic effect on HeLa cells with IC50 value of 160 μg/mL. |
| Animal experiment [2]: | |
Animal models | guinea pig wound chamber model |
Dosage form | 5 microM for 8 d |
Application | The ability of lovastatin to induce fibroblast apoptosis in vivo was examined using a guinea pig wound chamber model. Lovastatin (5 microM, 8 d) reduced granulation tissue formation in the wound chambers by 64.7%, with associated ultrastructural evidence of fibroblast apoptosis. |
Other notes | Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal. |
References: [1] Bhargavi S, et al. Purification of Lovastatin from Aspergillus terreus (KM017963) and Evaluation of its Anticancer and Antioxidant Properties. Asian Pac J Cancer Prev. 2016;17(8):3797-803. [2] Tobert JA, et al. Lovastatin and beyond: the history of the HMG-CoA reductase inhibitors. Nat Rev Drug Discov. 2003 Jul;2(7):517-26. | |
Lovastatin Dilution Calculator
calculate
Lovastatin Molarity Calculator
calculate
| Cas No. | 75330-75-5 | SDF | Download SDF |
| Synonyms | N/A | ||
| Chemical Name | [(1S,3R,7S,8S,8aR)-8-[2-[(2R,4R)-4-hydroxy-6-oxooxan-2-yl]ethyl]-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl] (2S)-2-methylbutanoate | ||
| Canonical SMILES | CCC(C)C(=O)OC1CC(C=C2C1C(C(C=C2)C)CCC3CC(CC(=O)O3)O)C | ||
| Formula | C24H36O5 | M.Wt | 404.54 |
| Solubility | ≥20.2 mg/mL in DMSO, ≥18.6 mg/mL in EtOH with ultrasonic, <2.39 mg/ml="" in="" h2o=""> | Storage | Store at -20°C |
| Shipping Condition | Evaluation sample solution : ship with blue ice.All other available size:ship with RT , or blue ice upon request | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. | ||
Lovastatin is an inhibitor of 3-hydroxy-3-methyl-glutaryl-CoA (HMG-CoA) reductase with IC50 values of 2.3 nmol/L in rat liver cells and 5 nmol/L in the human liver hepatocellular carcinoma cell line, HepG2 [1].
HMG-CoA reductase is responsible for the catalysis of the rate-limiting step in the biosynthesis of cholesterol. It catalyzes the conversion of HMG-CoA to mevalonate, the second step in the production of cholesterol in cells [2].
Lovastatin prevented the proliferation of several cell types by inhibiting the production of mevalonate and its metabolites. Inhibition of mevalonate formation also prevented the production of isoprenoids which are necessary for cell proliferation and other important cell functions. This reduction in isoprenoids caused beneficial pleiotropic effects. Lovastatin caused reduction in DNA synthesis at concentrations of 1 to 20 µM. At 1 µM, it inhibited the increase of mesangial cells in culture. Lovastatin (5 μM) also increased efferocytosis (phagocytosis of apoptotic cells) after 6 hours. However, after 24 hours, its effect was dose-dependent, with a maximum at 10 µM [3, 4, 5].
Mice treated with lovastatin (10 mg/kg) three times over 30 hours showed increased efferocytosis by alveolar macrophages. In a guinea pig wound chamber model, lovastatin (5 µM, 8 days) decreased granulation tissue formation by 64.7% [5, 6].
References: [1]. Amin D, Gustafson SK, Weinacht JM, et al. RG 12561 (Dalvastatin): A novel synthetic inhibitor of HMG-CoA reductase and cholesterol-lowering agent. Pharmacology, 1993, 46(1): 13-22.[2]. Tobert JA. Lovastatin and beyond: the history of the HMG-CoA reductase inhibitors. Nature Reviews Drug Discovery, 2003, 2(7): 517-526.[3]. Massy ZA, Keane WF, Kasiske BL. Inhibition of the mevalonate pathway: benefits beyond cholesterol reduction. The Lancet, 1996, 347(8994): 102-103.[4]. O"Donnell MP, Kasiske BL, Kim Y, et al. Lovastatin inhibits proliferation of rat mesangial cells. Journal of Clinical Investigation, 1993, 91(1): 83.[5]. Morimoto K, Janssen WJ, Fessler MB, et al. Lovastatin enhances clearance of apoptotic cells (efferocytosis) with implications for chronic obstructive pulmonary disease. The Journal of Immunology, 2006, 176(12): 7657-7665.[6]. Tan A, Levrey H, Dahm C, et al. Lovastatin induces fibroblast apoptosis in vitro and in vivo: a possible therapy for fibroproliferative disorders. American journal of respiratory and critical care medicine, 1999, 159(1): 220-227.
ebiomall.com
>
>
>
>
>
>
>
>
>
>
>
>
参考见解:只是固定方法不同。细胞固定用甲醇，切片固定用多聚甲醛，而染色方法是一样的。
2、问:近期要做免疫荧光双标，不知哪位有免疫荧光双标技术的详细步骤及其注意事项?
参考见解:我正在做冰冻组织切片的免疫荧光双染。我的经验是:
(1)选取一抗时要来源于两种不同的动物，我用的是来源于rabbit和rat的抗体，二抗则是不同荧光信号标记的，我用的是donkey anti-rabbit-FITC(绿)和donkey anti-rat-Tex-Red(红)。
(2)我的做法是两种一抗（CHI抗体）同时孵育，然后两种二抗同时孵育。抗体浓度、孵育时间要仔细摸索，我感觉一抗4度孵育过夜比较好，背景比较清晰。
(3)我的阳性对照用的是阳性组织切片，阴性对照则分别是家兔和大鼠的IgG，荧光标记物对照是PBS+荧光标记物。
(4)封闭血清与二抗来源动物一致，我用的是10%的正常donkey血清。
(5)其余步骤同一般免疫荧光单标操作。
3、问:本人拟做Brdu标记神经干细胞免疫荧光，二抗为FITC标记，想请教各位大侠:
(1)抗体分装和荧光显微镜观察时是否一定要在暗室中进行?
(2)封片时是否用甘油缓冲液即可，还是用甘油和0.5mmol/L pH9.0-9.5的碳酸氢盐缓冲液等量混合封片?
(3)免疫酶染色中的3%过氧化氢及2N盐酸是否还需要用?
参考见解:
(1)你的二抗是用FITC标记的，为避免荧光分解，分装及荧光显微镜观察时均要避光;
(2)封片最好用甘油加0.5mmol/L pH9.0-9.5的碳酸氢盐缓冲液，后者能使玻片透明;
(3)关于免疫酶染色，如果是用过氧化物酶做标记，就必须用3%H2O2以去除内源性过氧化物酶;2N盐酸需要使用，目的是使DNA变性，让Brdu抗体能够充分地与已经掺入的Brdu结合。
4、问:做间接法免疫荧光染色，如何设置对照?
参考见解:最好是同一视野在未用荧光激发下进行对照，看是否非特异性染色。
(1)空白对照:如果你做的是石蜡切片免疫组化，这个对照必须有，目的是看自发荧光，脱蜡后直接在荧光显微镜下观察。
(2)阴性对照:标本直接滴加二抗，呈阴性反应。
(3)抗原对照:标本加同种动物的未免疫血清，以PBS冲洗后，在加抗免疫球蛋白荧光抗体。因未免疫动物的血清中无特异性抗体，应呈阴性反应。
5、问:我做乳腺组织的免疫荧光染色，结果用激光共聚焦显微镜看很好:有阳性信号，阴性对照组也没有荧光，但是拿到荧光显微镜下看，我的阴性对照组一片绿，像非特异性染色，到底哪个结果才是真实的呢?
参考见解:激光共聚焦显微镜的分辨率比普通荧光显微镜要高的多，出现上述现象首先要排除荧光显微镜的问题，如是不是紫外灯泡寿命到期了或者别的原因，荧光显微镜没有问题，那就以共聚焦显微镜的结果为主。展开
2.-20度甲醇固定20分钟后,自然、干燥 10分钟
3.PBS洗净:3min*3
4.1%Triton:25min-30min.配成50ultriton+5mlpBS
5.PBS洗净:2*5min
6.羊血清封闭：37度，20分钟
7.一抗，4度过夜，一般要大于18小时或者37度 1-2小时
8.4度 PBS洗净，3min*5次
9.二抗 37度小于一小时
,我需要这个仪器有关的供应商的信息，有知道的人不，腾讯看你的专家团队给力不，想买这个仪器，但关于这个资料我已经了解很多了，但不知道去哪引进，哪里买。麻烦告诉哪里买，
血清封闭：组织切片上有剩余的位点可以与一抗非特异性结合，造成后续结果的假阳性；封闭血清一般是和二抗同一来源的，血清中动物自身的抗体，预先能和组织中有交叉反应的位点发生结合；也可以用小牛血清、BSA、羊血清等，但不能与一抗来源一致。
针对这个应该有详细的解说的
